In this study, we investigated the outcomes and factors influencing treatment efficacy in 93 patients with limited disease small cell lung cancer (LD-SCLC), with a median age of 64 years. We focused on the impact of chemotherapy regimens, prophylactic cranial irradiation (PCI), and patient-related variables. The median follow-up for OS was 17.3 months. We observed a statistically significant difference in PFS between LD-SCLC patients treated with cisplatin and etoposide (EP) and those treated with carboplatin and etoposide (CP) (PFS: EP 13.63 months vs. CP 6.54 months,p< 0.01). Patients treated with EP had better overall survival (OS) than CP-treated patients (OS: EP 26.9 months vs. CP 16.16 months,p< 0.01). Concomitant chemotherapy was associated with improved PFS (p= 0.003) and OS (p= 0.002). Patients receiving PCI showed superior OS (p= 0.05) and a trend towards improved PFS (p= 0.057). Female gender was associated with better OS (p= 0.025). Most patients had an ECOG performance status of 0 (71%). This real-world study underscores the importance of multidisciplinary LD-SCLC management, emphasizing the roles of chemotherapy, radiotherapy, and PCI. These findings inform personalized treatment strategies and emphasize the need for prospective trials to validate these results and optimize LD-SCLC treatment.
本研究对93例局限期小细胞肺癌（LD-SCLC）患者（中位年龄64岁）的治疗结果及影响因素进行了分析，重点关注化疗方案、预防性全脑放疗（PCI）及患者相关变量的影响。中位总生存期（OS）随访时间为17.3个月。研究发现，接受顺铂联合依托泊苷（EP）方案治疗的LD-SCLC患者与接受卡铂联合依托泊苷（CP）方案治疗的患者在无进展生存期（PFS）上存在统计学显著差异（EP组13.63个月 vs CP组6.54个月，p<0.01）。EP治疗组患者的总生存期（OS）也优于CP治疗组（EP组26.9个月 vs CP组16.16个月，p<0.01）。同步放化疗与PFS（p=0.003）和OS（p=0.002）的改善显著相关。接受PCI治疗的患者显示出更优的OS（p=0.05），且PFS有改善趋势（p=0.057）。女性患者与更好的OS相关（p=0.025）。大多数患者ECOG体能状态评分为0分（71%）。这项真实世界研究强调了多学科综合治疗在LD-SCLC管理中的重要性，突出了化疗、放疗及PCI的作用。研究结果为个体化治疗策略提供了依据，并强调需要通过前瞻性试验验证这些发现以优化LD-SCLC的治疗方案。
肿瘤(癌症)患者之家